Start-ups are developing engineered macrophages and regulatory T cells that may reverse the immune drivers of disease.
Regenerative medicines. Expanding on the success of cell therapy in hematological malignancies, investors put $300 million in 2022 toward cell therapies that can tackle the effects of complex degenerative conditions such as chronic liver and kidney diseases. Start-ups are developing engineered macrophages and regulatory T cells that may reverse the immune drivers of disease. Others are hoping to reverse fibrotic damage and promote new tissue growth in damaged organs using reprogrammed stem cells.